UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 1, 2011**

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-21846	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

8910 University Center Lane, Suite 660 **San Diego, California**	**92122**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(858) 459-7800**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

The Registrant disclosed that at 9:05 am EST this morning, March 1, 2011, it made a presentation at the Wall Street Analyst Forum 22nd Annual Investor Conference in New York, New York. A copy of the investor presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. Also, the Registrant posted the investor presentation materials to its website (www.aethlonmedical.com) today, March 1, 2011.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

Exhibit No.	Description
99.1	Wall Street Analyst Forum Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.
(Registrant)

Date: March 1, 2011

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Investor Presentation Materials

Exhibit 99.1


aethlon
MEDICAL, INC.
Wall Street Analyst Forum
March 1, 2011
Jim Joyce
Chairman, CEO



Forward Looking Statements

MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS ARE SUCCESSFULLY DEVELOPED AND

A revolutionary platform technology with broad therapeutic applications against infectious disease and cancer

aethlon MEDICAL, INC.

The Hemopurifier®

The first medical device to selectively remove infectious viruses and immunosuppressive toxins from circulation

Dual Benefit of Action

Simultaneous Antiviral & Immunotherapeutic

- Antiviral
  - Rapid real-time clearance of infectious viral pathogens
- Immunotherapeutic
  - Clearance of virally-shed and cancer-secreted toxins

aethlon MEDICAL, INC.

Our Circle of Opportunity



aethlon MEDICAL, INC.

Therapeutic Filtration

The Opportunity To Transition Beyond Kidney Dialysis



Market Opportunity	Application
HCV	standard of care adjunc
HIV	drug resistant patients
Bioterror & Pandemic Threats	broad-spectrum countermeasure
CANCER	immunotherapy / diagnost biomarker

Our Hemopurifier® has the advantage of being delivered through an established global infrastructure of dialysis stations (90,000+ in U.S. alone)

Additional Infrastructure to Deliver Hemopurifier® Therapy Includes:

- CRRT machines already located in hospitals and clinics
- Portable pump configurations

The Future

Home Infectious Disease & Cancer Therapy

aethlon MEDICAL, INC.

Genesis of our Hemopurifier®

A 2004 patent submission entitled “A Method for Removal of Viruses from Blood by Lectin Affinity Hemodialysis” which issued in 2007

aethlon MEDICAL, INC.

Since 2004

- Broadened our intellectual property portfolio
- Completed 11 pre-clinical programs that have validated broad-spectrum effectiveness in capturing infectious viral pathogens
- Completed 3 separate human safety studies conducted at the Apollo, Fortis, and Sigma New Life hospitals in India. (68 treatments)
- Demonstrated substantial viral load reductions in HIV and HCV infected patients in the absence of drug therapy
- Initiated HCV adjunct clinical study designed to accelerate benefit of SOC drug therapy
- Submitted an IDE to the FDA to initiate human studies in the United States
- Established GMP manufacturing and have signed LOI to expand capabilities

What Are Exosomes?

aethlon MEDICAL, INC.

Exosomes Are Secreted By:

- All solid-form tumors
- Lymphomas
- Leukemias

aethlon MEDICAL, INC.

Science Publications Indicate That Exosomes

- Induce Apoptosis
- Disrupt t-cell signaling
- Inhibit cytokine production
- Angiogenesis
- Metastasis

aethlon MEDICAL, INC.

Tumor Secreted Exosomes



Pre-Clinical Hemopurifier® Cancer Validations

- Ovarian (2008)
- Breast (2010)
- Colorectal (2010)
- Lymphoma (2010)
- Melanoma (2010)
- Additional Studies (2011)

aethlon MEDICAL, INC.

Our Exosome Therapeutic Opportunity

- The Hemopurifier® fills a previously unmet medical need in cancer care
- Provides mechanism to preserve immune function
- Serves as an adjunct to improve benefit of established and candidate cancer therapies

aethlon MEDICAL, INC.


600
aethlon
MEDICAL, INC.



Human Immunodeficiency Virus (HIV)

A Solution to Drug Resistance

HIV-AIDS Study

- Infected dialysis patient
- 12 treatments / 30 days
- 4 hrs per treatment
- Performed in absence of drug therapy
- Average per treatment viral load reduction of 54%
- Improved CD4 t-cell ratios



Bioterrorism & Pandemic Threats

Why Return to the Biodefense & Pandemic Threat Space?

- HHS is committed to increasing countermeasure support
- Focal shift from one-drug-one-bug to broad-spectrum therapie
- Countermeasures with commercial market applications now ok
- FDA approval not required for stockpile consideration
- Non-dilutive funding available in amounts not limited by our market value

aethlon MEDICAL, INC.

U.S. Department of Health and Human Services
BARDA Industry Day Presentation

Washington, DC
January 12, 2011

James A. Joyce



A Broad-Spectrum Antiviral Platform Technolo

The New BARDA & PHEMCE Strategic Objectives

- To identify and support the development of innovative broad-spectrum:
  - Countermeasures
  - Technologies
  - Platforms
- Strategies that address traditional, enhanced, emerging, and advanced threats
- Adjunct or adjuvant therapies that improve countermeasure performance

aethlon MEDICAL, INC.

In Vitro Confirmations Against Bioterror and Pandemic Threats

Virus	Collaborator
Ebola	USAMRIID/CDC
Dengue	NIV/WHO
Lassa	SFBR
West Nile	Battelle
H5N1 Avian	Battelle
1918-r Spanish Flu	Battelle
2009 H1N1 Swine	Battelle

The Hemopurifier® represents the most advanced broad-spectrum countermeasure against bioterror and
emerging pandemic threats

"The Aethlon Hemopurifier® is the only strategy to address the breadth of pathogens that could be weaponized as agents of bioterrorism."

Ken Alibek
Director of USSR Bioweapon Program
Author of "BIOHAZARD"

Current Activities

- Active CRADA with USAMRIID
- Defining program opportunities with BARDA
- Awaiting a BAA from DTRA
- Preparing response to BAA (released on 2/8/11) from DARPA entitled “Dialysis Like Therapeutics”



Hepatitis-C Virus (HCV)

Our #1 Priority

Why HCV?

- 180 million infected
- Low response rate to peg-interferon/ribavirin standard of care (SOC) drug therapy
- Valuations awarded to organizations with promising adjunct data (Telaprevir from Vertex:VRTX $8.9 bn)
- Clinical validation that viral filtration improves HCV cure rates

aethlon MEDICAL, INC.

Advantages of Therapeutic Filtration as an Adjunct to SOC

- Improves viral clearance without adding drug toxicity
- Improves viral clearance without introducing new drug interaction risks
- Provides a mechanism to address all genotypes of HCV
- A device has an enduring opportunity to improve benefit of current and future iterations of SOC drug therapy

aethlon MEDICAL, INC.

Two therapeutic filtration strategies have been tested in HCV infected patients

- The VRAD, a market approved device from Asahi Kasei Kuraray Medical CO. (Japan)
- The Hemopurifier®, a clinical stage device from Aethlon Medical, Inc. (United States)

The Treatment of HCV Genotype-1 Non-Responders



The Hemopurifier® vs. VRAD Viral Depletion Analysis

- Average VRAD treatment period of 3 hrs 14 min with benefit of SOC drug therapy (n=72 treatments)
- Average Hemopurifier® treatment period of 4 hrs in absence of SOC drug therapy benefit (n=24 treatments)



The Hemopurifier® vs. VRAD

- In addition to improving viral clearance
- The Hemopurifier® provides a selective capture mechanism which allows for greater safety and optimization of treatment outcomes
- The Hemopurifier® removes immunosuppressive proteins shed by HCV that cannot be addressed by VRAD
- The Hemopurifier® is a sealed single-use disposable cartridge vs. multiple cartridge and pump set-required by VRAD

aethlon MEDICAL, INC.

The Hemopurifier® + SOC?

- Initiated clinical study at the Medanta Medicity Institute
- Up to 30 patients / up to 6 treatments in first 3 days of SOC
- Early clinical endpoints include:
  - Immediate Virologic Response (IVR)
  - Rapid Virologic Response (RVR)
  - Early Virologic Response (EVR)
- Commercialization triggered upon positive outcomes

aethlon MEDICAL, INC.

Our foundation to drive shareholder value in 2011

- Positive HCV data
- Transition from R&D to revenue generation
  - Commercialization
  - Contract-grant income
- FDA approval to initiate U.S. clinical programs
- New cancer research data
- Strategic relationships (infectious disease and cancer)

aethlon MEDICAL, INC.

A revolutionary platform technology with broad therapeutic applications against infectious disease and cancer

aethlon MEDICAL, INC.

aethlon MEDICAL, INC.

8910 University Center Lane, Suite 660

San Diego, CA. 92122

www.AethlonMedical.com



Presenter Information

Jim Joyce

Chairman, CEO

Aethlon Medical, Inc.

(858) 459-7800 x301

jj@aethlonmedical.com